nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—Protein Kinase Inhibitors—Sunitinib—pancreatic cancer	0.26	1	CiPCiCtD
Vandetanib—Erlotinib—pancreatic cancer	0.251	1	CrCtD
Vandetanib—Gefitinib—Erlotinib—pancreatic cancer	0.109	1	CrCrCtD
Vandetanib—SRC—pancreatic cancer	0.0353	0.293	CbGaD
Vandetanib—KDR—pancreatic cancer	0.0331	0.276	CbGaD
Vandetanib—VEGFA—pancreatic cancer	0.0281	0.234	CbGaD
Vandetanib—EGFR—pancreatic cancer	0.0237	0.197	CbGaD
Vandetanib—MKNK1—Erlotinib—pancreatic cancer	0.00903	0.0494	CbGbCtD
Vandetanib—LTK—Erlotinib—pancreatic cancer	0.00903	0.0494	CbGbCtD
Vandetanib—FMO1—Tamoxifen—pancreatic cancer	0.00889	0.0486	CbGbCtD
Vandetanib—SLK—Erlotinib—pancreatic cancer	0.00756	0.0413	CbGbCtD
Vandetanib—FLT3—Erlotinib—pancreatic cancer	0.00653	0.0357	CbGbCtD
Vandetanib—FYN—Sunitinib—pancreatic cancer	0.00595	0.0325	CbGbCtD
Vandetanib—AXL—Sunitinib—pancreatic cancer	0.00595	0.0325	CbGbCtD
Vandetanib—IRAK4—Sunitinib—pancreatic cancer	0.00595	0.0325	CbGbCtD
Vandetanib—TYRO3—Sunitinib—pancreatic cancer	0.00595	0.0325	CbGbCtD
Vandetanib—EPHA6—Erlotinib—pancreatic cancer	0.00577	0.0316	CbGbCtD
Vandetanib—FMO3—Tamoxifen—pancreatic cancer	0.00555	0.0304	CbGbCtD
Vandetanib—ABL2—Erlotinib—pancreatic cancer	0.00519	0.0284	CbGbCtD
Vandetanib—EGFR—Erlotinib—pancreatic cancer	0.00519	0.0284	CbGbCtD
Vandetanib—STK10—Erlotinib—pancreatic cancer	0.00519	0.0284	CbGbCtD
Vandetanib—PLK4—Sunitinib—pancreatic cancer	0.00498	0.0272	CbGbCtD
Vandetanib—SLK—Sunitinib—pancreatic cancer	0.00498	0.0272	CbGbCtD
Vandetanib—YES1—Sunitinib—pancreatic cancer	0.00498	0.0272	CbGbCtD
Vandetanib—FLT4—Sunitinib—pancreatic cancer	0.00498	0.0272	CbGbCtD
Vandetanib—MAP4K5—Sunitinib—pancreatic cancer	0.00498	0.0272	CbGbCtD
Vandetanib—MAP2K5—Erlotinib—pancreatic cancer	0.00472	0.0258	CbGbCtD
Vandetanib—MAP3K19—Erlotinib—pancreatic cancer	0.00434	0.0237	CbGbCtD
Vandetanib—FLT3—Sunitinib—pancreatic cancer	0.0043	0.0235	CbGbCtD
Vandetanib—FGR—Sunitinib—pancreatic cancer	0.0043	0.0235	CbGbCtD
Vandetanib—KDR—Sunitinib—pancreatic cancer	0.0043	0.0235	CbGbCtD
Vandetanib—RET—Sunitinib—pancreatic cancer	0.0043	0.0235	CbGbCtD
Vandetanib—EPHB6—Sunitinib—pancreatic cancer	0.0038	0.0208	CbGbCtD
Vandetanib—BLK—Sunitinib—pancreatic cancer	0.0038	0.0208	CbGbCtD
Vandetanib—ABL1—Erlotinib—pancreatic cancer	0.00375	0.0205	CbGbCtD
Vandetanib—EGFR—Docetaxel—pancreatic cancer	0.00343	0.0188	CbGbCtD
Vandetanib—STK10—Sunitinib—pancreatic cancer	0.00342	0.0187	CbGbCtD
Vandetanib—MAP2K5—Sunitinib—pancreatic cancer	0.00311	0.017	CbGbCtD
Vandetanib—PDGFRB—Sunitinib—pancreatic cancer	0.00311	0.017	CbGbCtD
Vandetanib—MAP3K19—Sunitinib—pancreatic cancer	0.00286	0.0156	CbGbCtD
Vandetanib—RET—enteric nervous system—pancreatic cancer	0.00235	0.232	CbGeAlD
Vandetanib—ORM1—Erlotinib—pancreatic cancer	0.0014	0.00768	CbGbCtD
Vandetanib—ABCC1—Epirubicin—pancreatic cancer	0.00119	0.0065	CbGbCtD
Vandetanib—ABCC1—Irinotecan—pancreatic cancer	0.00116	0.00632	CbGbCtD
Vandetanib—ABCG2—Tamoxifen—pancreatic cancer	0.00101	0.00551	CbGbCtD
Vandetanib—ABCG2—Erlotinib—pancreatic cancer	0.000857	0.00468	CbGbCtD
Vandetanib—ABCC1—Docetaxel—pancreatic cancer	0.000847	0.00463	CbGbCtD
Vandetanib—ABCG2—Irinotecan—pancreatic cancer	0.000774	0.00423	CbGbCtD
Vandetanib—ORM1—bile—pancreatic cancer	0.000745	0.0738	CbGeAlD
Vandetanib—ABCG2—Fluorouracil—pancreatic cancer	0.000743	0.00406	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—pancreatic cancer	0.000632	0.00345	CbGbCtD
Vandetanib—KDR—umbilical vein—pancreatic cancer	0.000619	0.0613	CbGeAlD
Vandetanib—ALB—Erlotinib—pancreatic cancer	0.000591	0.00323	CbGbCtD
Vandetanib—ABCG2—Docetaxel—pancreatic cancer	0.000567	0.0031	CbGbCtD
Vandetanib—ABCG2—Sunitinib—pancreatic cancer	0.000564	0.00309	CbGbCtD
Vandetanib—ALB—Irinotecan—pancreatic cancer	0.000533	0.00292	CbGbCtD
Vandetanib—ALB—Fluorouracil—pancreatic cancer	0.000512	0.0028	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—pancreatic cancer	0.000423	0.00231	CbGbCtD
Vandetanib—STK35—islet of Langerhans—pancreatic cancer	0.000274	0.0271	CbGeAlD
Vandetanib—PTK6—digestive system—pancreatic cancer	0.000255	0.0253	CbGeAlD
Vandetanib—RIPK2—islet of Langerhans—pancreatic cancer	0.000253	0.025	CbGeAlD
Vandetanib—VEGFA—islet of Langerhans—pancreatic cancer	0.000252	0.025	CbGeAlD
Vandetanib—IRAK4—islet of Langerhans—pancreatic cancer	0.000247	0.0244	CbGeAlD
Vandetanib—Afatinib—EGFR—pancreatic cancer	0.000238	0.309	CrCbGaD
Vandetanib—PDGFRB—gall bladder—pancreatic cancer	0.00022	0.0218	CbGeAlD
Vandetanib—CYP3A4—Tamoxifen—pancreatic cancer	0.000218	0.00119	CbGbCtD
Vandetanib—SLK—islet of Langerhans—pancreatic cancer	0.000215	0.0213	CbGeAlD
Vandetanib—ORM1—gall bladder—pancreatic cancer	0.000207	0.0205	CbGeAlD
Vandetanib—MAP4K5—islet of Langerhans—pancreatic cancer	0.000204	0.0202	CbGeAlD
Vandetanib—EPHA5—digestive system—pancreatic cancer	0.000197	0.0196	CbGeAlD
Vandetanib—EPHB6—islet of Langerhans—pancreatic cancer	0.000195	0.0193	CbGeAlD
Vandetanib—STK35—pancreas—pancreatic cancer	0.000193	0.0191	CbGeAlD
Vandetanib—YES1—islet of Langerhans—pancreatic cancer	0.000189	0.0187	CbGeAlD
Vandetanib—CYP3A4—Erlotinib—pancreatic cancer	0.000185	0.00101	CbGbCtD
Vandetanib—SRC—islet of Langerhans—pancreatic cancer	0.000182	0.018	CbGeAlD
Vandetanib—ALB—gall bladder—pancreatic cancer	0.000181	0.018	CbGeAlD
Vandetanib—VEGFA—pancreas—pancreatic cancer	0.000177	0.0175	CbGeAlD
Vandetanib—PLK4—Topotecan—Irinotecan—pancreatic cancer	0.000173	0.257	CbGdCrCtD
Vandetanib—ERBB3—pancreas—pancreatic cancer	0.00017	0.0168	CbGeAlD
Vandetanib—Erlotinib—EGFR—pancreatic cancer	0.000168	0.219	CrCbGaD
Vandetanib—CYP3A4—Irinotecan—pancreatic cancer	0.000167	0.000914	CbGbCtD
Vandetanib—Bosutinib—SRC—pancreatic cancer	0.000154	0.2	CrCbGaD
Vandetanib—RIPK2—digestive system—pancreatic cancer	0.000152	0.015	CbGeAlD
Vandetanib—SLK—pancreas—pancreatic cancer	0.000151	0.015	CbGeAlD
Vandetanib—FMO1—digestive system—pancreatic cancer	0.00015	0.0149	CbGeAlD
Vandetanib—ABL1—Topotecan—Irinotecan—pancreatic cancer	0.000146	0.216	CbGdCrCtD
Vandetanib—ERBB3—digestive system—pancreatic cancer	0.000145	0.0144	CbGeAlD
Vandetanib—PDGFRB—islet of Langerhans—pancreatic cancer	0.000145	0.0143	CbGeAlD
Vandetanib—TEK—pancreas—pancreatic cancer	0.000144	0.0142	CbGeAlD
Vandetanib—MAP4K5—pancreas—pancreatic cancer	0.000144	0.0142	CbGeAlD
Vandetanib—MKNK1—digestive system—pancreatic cancer	0.000136	0.0135	CbGeAlD
Vandetanib—FGR—digestive system—pancreatic cancer	0.000135	0.0133	CbGeAlD
Vandetanib—RET—digestive system—pancreatic cancer	0.000135	0.0133	CbGeAlD
Vandetanib—YES1—pancreas—pancreatic cancer	0.000133	0.0131	CbGeAlD
Vandetanib—ABL1—islet of Langerhans—pancreatic cancer	0.000129	0.0128	CbGeAlD
Vandetanib—SRC—pancreas—pancreatic cancer	0.000128	0.0126	CbGeAlD
Vandetanib—FYN—digestive system—pancreatic cancer	0.000126	0.0124	CbGeAlD
Vandetanib—CYP3A4—Docetaxel—pancreatic cancer	0.000122	0.00067	CbGbCtD
Vandetanib—CYP3A4—Sunitinib—pancreatic cancer	0.000122	0.000667	CbGbCtD
Vandetanib—YES1—digestive system—pancreatic cancer	0.000113	0.0112	CbGeAlD
Vandetanib—STK10—digestive system—pancreatic cancer	0.000112	0.0111	CbGeAlD
Vandetanib—SRC—digestive system—pancreatic cancer	0.000109	0.0108	CbGeAlD
Vandetanib—Gefitinib—EGFR—pancreatic cancer	0.000105	0.137	CrCbGaD
Vandetanib—Bosutinib—EGFR—pancreatic cancer	0.000104	0.135	CrCbGaD
Vandetanib—PDGFRB—pancreas—pancreatic cancer	0.000102	0.0101	CbGeAlD
Vandetanib—KDR—digestive system—pancreatic cancer	0.0001	0.00993	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—pancreatic cancer	9.13e-05	0.000499	CbGbCtD
Vandetanib—ABL1—pancreas—pancreatic cancer	9.05e-05	0.00897	CbGeAlD
Vandetanib—PDGFRB—digestive system—pancreatic cancer	8.68e-05	0.00859	CbGeAlD
Vandetanib—ABL1—digestive system—pancreatic cancer	7.73e-05	0.00766	CbGeAlD
Vandetanib—PLK4—Doxorubicin—Epirubicin—pancreatic cancer	4.08e-05	0.0605	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Epirubicin—pancreatic cancer	4.08e-05	0.0605	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—pancreatic cancer	3.77e-05	0.056	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Doxorubicin—pancreatic cancer	3.77e-05	0.056	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—pancreatic cancer	3.43e-05	0.0508	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—pancreatic cancer	3.43e-05	0.0508	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—pancreatic cancer	3.43e-05	0.0508	CbGdCrCtD
Vandetanib—CYP3A4—digestive system—pancreatic cancer	3.4e-05	0.00336	CbGeAlD
Vandetanib—ABL1—Epirubicin—Doxorubicin—pancreatic cancer	3.17e-05	0.047	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—pancreatic cancer	3.17e-05	0.047	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—pancreatic cancer	3.17e-05	0.047	CbGdCrCtD
Vandetanib—Nasopharyngitis—Epirubicin—pancreatic cancer	1.67e-05	0.000534	CcSEcCtD
Vandetanib—Malnutrition—Docetaxel—pancreatic cancer	1.67e-05	0.000533	CcSEcCtD
Vandetanib—Decreased appetite—Gemcitabine—pancreatic cancer	1.67e-05	0.000533	CcSEcCtD
Vandetanib—Dyspepsia—Fluorouracil—pancreatic cancer	1.66e-05	0.00053	CcSEcCtD
Vandetanib—Nausea—Tamoxifen—pancreatic cancer	1.66e-05	0.00053	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	1.66e-05	0.000529	CcSEcCtD
Vandetanib—Fatigue—Gemcitabine—pancreatic cancer	1.65e-05	0.000528	CcSEcCtD
Vandetanib—Gastritis—Epirubicin—pancreatic cancer	1.65e-05	0.000528	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	1.65e-05	0.000526	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—pancreatic cancer	1.64e-05	0.000525	CcSEcCtD
Vandetanib—Pain—Gemcitabine—pancreatic cancer	1.64e-05	0.000524	CcSEcCtD
Vandetanib—Constipation—Gemcitabine—pancreatic cancer	1.64e-05	0.000524	CcSEcCtD
Vandetanib—Nausea—Erlotinib—pancreatic cancer	1.64e-05	0.000524	CcSEcCtD
Vandetanib—Decreased appetite—Fluorouracil—pancreatic cancer	1.64e-05	0.000524	CcSEcCtD
Vandetanib—Diarrhoea—Sunitinib—pancreatic cancer	1.64e-05	0.000523	CcSEcCtD
Vandetanib—Dysgeusia—Docetaxel—pancreatic cancer	1.63e-05	0.000522	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	1.63e-05	0.00052	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—pancreatic cancer	1.62e-05	0.000517	CcSEcCtD
Vandetanib—Influenza—Epirubicin—pancreatic cancer	1.62e-05	0.000516	CcSEcCtD
Vandetanib—Dysphagia—Epirubicin—pancreatic cancer	1.62e-05	0.000516	CcSEcCtD
Vandetanib—Pain—Fluorouracil—pancreatic cancer	1.61e-05	0.000515	CcSEcCtD
Vandetanib—Gastrointestinal pain—Irinotecan—pancreatic cancer	1.61e-05	0.000514	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—pancreatic cancer	1.61e-05	0.000514	CcSEcCtD
Vandetanib—Muscle spasms—Docetaxel—pancreatic cancer	1.6e-05	0.000512	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—pancreatic cancer	1.59e-05	0.000506	CcSEcCtD
Vandetanib—Pancreatitis—Epirubicin—pancreatic cancer	1.58e-05	0.000506	CcSEcCtD
Vandetanib—Dizziness—Sunitinib—pancreatic cancer	1.58e-05	0.000505	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—pancreatic cancer	1.57e-05	0.000503	CcSEcCtD
Vandetanib—Abdominal pain—Irinotecan—pancreatic cancer	1.56e-05	0.000497	CcSEcCtD
Vandetanib—Body temperature increased—Irinotecan—pancreatic cancer	1.56e-05	0.000497	CcSEcCtD
Vandetanib—Bronchitis—Epirubicin—pancreatic cancer	1.55e-05	0.000496	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—pancreatic cancer	1.55e-05	0.000494	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—pancreatic cancer	1.53e-05	0.000489	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	1.53e-05	0.000487	CcSEcCtD
Vandetanib—Vomiting—Sunitinib—pancreatic cancer	1.52e-05	0.000486	CcSEcCtD
Vandetanib—Body temperature increased—Gemcitabine—pancreatic cancer	1.52e-05	0.000484	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—pancreatic cancer	1.51e-05	0.000482	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—pancreatic cancer	1.51e-05	0.000482	CcSEcCtD
Vandetanib—Rash—Sunitinib—pancreatic cancer	1.51e-05	0.000482	CcSEcCtD
Vandetanib—Dermatitis—Sunitinib—pancreatic cancer	1.51e-05	0.000481	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—pancreatic cancer	1.5e-05	0.000479	CcSEcCtD
Vandetanib—Headache—Sunitinib—pancreatic cancer	1.5e-05	0.000478	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—pancreatic cancer	1.49e-05	0.000477	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—pancreatic cancer	1.49e-05	0.000477	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—pancreatic cancer	1.49e-05	0.000477	CcSEcCtD
Vandetanib—Body temperature increased—Fluorouracil—pancreatic cancer	1.49e-05	0.000476	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—pancreatic cancer	1.47e-05	0.000471	CcSEcCtD
Vandetanib—Loss of consciousness—Docetaxel—pancreatic cancer	1.47e-05	0.000468	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—pancreatic cancer	1.47e-05	0.000468	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—pancreatic cancer	1.46e-05	0.000467	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—pancreatic cancer	1.46e-05	0.000465	CcSEcCtD
Vandetanib—Cough—Docetaxel—pancreatic cancer	1.46e-05	0.000465	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—pancreatic cancer	1.45e-05	0.000463	CcSEcCtD
Vandetanib—Convulsion—Docetaxel—pancreatic cancer	1.45e-05	0.000462	CcSEcCtD
Vandetanib—Hypertension—Docetaxel—pancreatic cancer	1.44e-05	0.00046	CcSEcCtD
Vandetanib—Infestation—Epirubicin—pancreatic cancer	1.44e-05	0.00046	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—pancreatic cancer	1.44e-05	0.00046	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—pancreatic cancer	1.44e-05	0.000459	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	1.43e-05	0.000456	CcSEcCtD
Vandetanib—Arthralgia—Docetaxel—pancreatic cancer	1.42e-05	0.000454	CcSEcCtD
Vandetanib—Chest pain—Docetaxel—pancreatic cancer	1.42e-05	0.000454	CcSEcCtD
Vandetanib—Nausea—Sunitinib—pancreatic cancer	1.42e-05	0.000454	CcSEcCtD
Vandetanib—Renal failure—Epirubicin—pancreatic cancer	1.42e-05	0.000452	CcSEcCtD
Vandetanib—Asthenia—Irinotecan—pancreatic cancer	1.41e-05	0.000451	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	1.41e-05	0.000451	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—pancreatic cancer	1.4e-05	0.000448	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—pancreatic cancer	1.4e-05	0.000447	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—pancreatic cancer	1.4e-05	0.000447	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—pancreatic cancer	1.4e-05	0.000446	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—pancreatic cancer	1.4e-05	0.000446	CcSEcCtD
Vandetanib—Dry mouth—Docetaxel—pancreatic cancer	1.39e-05	0.000444	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	1.39e-05	0.000444	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—pancreatic cancer	1.38e-05	0.000441	CcSEcCtD
Vandetanib—Asthenia—Gemcitabine—pancreatic cancer	1.38e-05	0.00044	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—pancreatic cancer	1.37e-05	0.000439	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—pancreatic cancer	1.36e-05	0.000436	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—pancreatic cancer	1.36e-05	0.000435	CcSEcCtD
Vandetanib—Oedema—Docetaxel—pancreatic cancer	1.36e-05	0.000435	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—pancreatic cancer	1.36e-05	0.000434	CcSEcCtD
Vandetanib—Pruritus—Gemcitabine—pancreatic cancer	1.36e-05	0.000434	CcSEcCtD
Vandetanib—Infection—Docetaxel—pancreatic cancer	1.35e-05	0.000432	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—pancreatic cancer	1.35e-05	0.000432	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—pancreatic cancer	1.35e-05	0.000431	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—pancreatic cancer	1.35e-05	0.000431	CcSEcCtD
Vandetanib—Diarrhoea—Irinotecan—pancreatic cancer	1.35e-05	0.00043	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—pancreatic cancer	1.34e-05	0.000428	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—pancreatic cancer	1.34e-05	0.000426	CcSEcCtD
Vandetanib—Pruritus—Fluorouracil—pancreatic cancer	1.33e-05	0.000426	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—pancreatic cancer	1.33e-05	0.000426	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—pancreatic cancer	1.33e-05	0.000426	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—pancreatic cancer	1.33e-05	0.000426	CcSEcCtD
Vandetanib—Skin disorder—Docetaxel—pancreatic cancer	1.32e-05	0.000422	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	1.32e-05	0.000422	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—pancreatic cancer	1.32e-05	0.00042	CcSEcCtD
Vandetanib—Diarrhoea—Gemcitabine—pancreatic cancer	1.31e-05	0.000419	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—pancreatic cancer	1.31e-05	0.000418	CcSEcCtD
Vandetanib—Dizziness—Irinotecan—pancreatic cancer	1.3e-05	0.000416	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—pancreatic cancer	1.3e-05	0.000415	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—pancreatic cancer	1.3e-05	0.000415	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—pancreatic cancer	1.3e-05	0.000414	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—pancreatic cancer	1.3e-05	0.000414	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—pancreatic cancer	1.29e-05	0.000413	CcSEcCtD
Vandetanib—Diarrhoea—Fluorouracil—pancreatic cancer	1.29e-05	0.000412	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—pancreatic cancer	1.28e-05	0.000408	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—pancreatic cancer	1.27e-05	0.000406	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—pancreatic cancer	1.27e-05	0.000405	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	1.26e-05	0.000402	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—pancreatic cancer	1.26e-05	0.000401	CcSEcCtD
Vandetanib—Vomiting—Irinotecan—pancreatic cancer	1.25e-05	0.0004	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—pancreatic cancer	1.25e-05	0.000399	CcSEcCtD
Vandetanib—Dizziness—Fluorouracil—pancreatic cancer	1.25e-05	0.000398	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—pancreatic cancer	1.25e-05	0.000398	CcSEcCtD
Vandetanib—Rash—Irinotecan—pancreatic cancer	1.24e-05	0.000397	CcSEcCtD
Vandetanib—Dermatitis—Irinotecan—pancreatic cancer	1.24e-05	0.000396	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	1.24e-05	0.000396	CcSEcCtD
Vandetanib—Headache—Irinotecan—pancreatic cancer	1.23e-05	0.000394	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—pancreatic cancer	1.23e-05	0.000393	CcSEcCtD
Vandetanib—Paraesthesia—Docetaxel—pancreatic cancer	1.22e-05	0.000391	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—pancreatic cancer	1.22e-05	0.00039	CcSEcCtD
Vandetanib—Vomiting—Gemcitabine—pancreatic cancer	1.22e-05	0.00039	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—pancreatic cancer	1.22e-05	0.000389	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—pancreatic cancer	1.21e-05	0.000388	CcSEcCtD
Vandetanib—Rash—Gemcitabine—pancreatic cancer	1.21e-05	0.000386	CcSEcCtD
Vandetanib—Dermatitis—Gemcitabine—pancreatic cancer	1.21e-05	0.000386	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—pancreatic cancer	1.21e-05	0.000386	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—pancreatic cancer	1.2e-05	0.000384	CcSEcCtD
Vandetanib—Headache—Gemcitabine—pancreatic cancer	1.2e-05	0.000384	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—pancreatic cancer	1.2e-05	0.000383	CcSEcCtD
Vandetanib—Vomiting—Fluorouracil—pancreatic cancer	1.2e-05	0.000383	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—pancreatic cancer	1.2e-05	0.000383	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—pancreatic cancer	1.2e-05	0.000382	CcSEcCtD
Vandetanib—Rash—Fluorouracil—pancreatic cancer	1.19e-05	0.00038	CcSEcCtD
Vandetanib—Dermatitis—Fluorouracil—pancreatic cancer	1.19e-05	0.00038	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—pancreatic cancer	1.18e-05	0.000378	CcSEcCtD
Vandetanib—Headache—Fluorouracil—pancreatic cancer	1.18e-05	0.000377	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—pancreatic cancer	1.18e-05	0.000377	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	1.18e-05	0.000375	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—pancreatic cancer	1.17e-05	0.000375	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—pancreatic cancer	1.17e-05	0.000375	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—pancreatic cancer	1.17e-05	0.000374	CcSEcCtD
Vandetanib—Nausea—Irinotecan—pancreatic cancer	1.17e-05	0.000374	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—pancreatic cancer	1.17e-05	0.000372	CcSEcCtD
Vandetanib—Pain—Docetaxel—pancreatic cancer	1.16e-05	0.000372	CcSEcCtD
Vandetanib—Constipation—Docetaxel—pancreatic cancer	1.16e-05	0.000372	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—pancreatic cancer	1.15e-05	0.000369	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—pancreatic cancer	1.15e-05	0.000368	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—pancreatic cancer	1.14e-05	0.000365	CcSEcCtD
Vandetanib—Nausea—Gemcitabine—pancreatic cancer	1.14e-05	0.000364	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—pancreatic cancer	1.13e-05	0.000362	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—pancreatic cancer	1.13e-05	0.000361	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—pancreatic cancer	1.13e-05	0.000359	CcSEcCtD
Vandetanib—Nausea—Fluorouracil—pancreatic cancer	1.12e-05	0.000358	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—pancreatic cancer	1.12e-05	0.000357	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—pancreatic cancer	1.11e-05	0.000356	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—pancreatic cancer	1.11e-05	0.000355	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—pancreatic cancer	1.1e-05	0.000352	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—pancreatic cancer	1.09e-05	0.000347	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—pancreatic cancer	1.08e-05	0.000346	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—pancreatic cancer	1.08e-05	0.000344	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—pancreatic cancer	1.08e-05	0.000344	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—pancreatic cancer	1.08e-05	0.000344	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—pancreatic cancer	1.07e-05	0.000341	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—pancreatic cancer	1.06e-05	0.000339	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—pancreatic cancer	1.06e-05	0.000338	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—pancreatic cancer	1.05e-05	0.000335	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—pancreatic cancer	1.04e-05	0.000333	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—pancreatic cancer	1.02e-05	0.000326	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—pancreatic cancer	1e-05	0.00032	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—pancreatic cancer	9.89e-06	0.000316	CcSEcCtD
Vandetanib—Cough—Epirubicin—pancreatic cancer	9.82e-06	0.000314	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—pancreatic cancer	9.81e-06	0.000313	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—pancreatic cancer	9.77e-06	0.000312	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—pancreatic cancer	9.75e-06	0.000311	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—pancreatic cancer	9.72e-06	0.00031	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—pancreatic cancer	9.63e-06	0.000308	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—pancreatic cancer	9.58e-06	0.000306	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—pancreatic cancer	9.58e-06	0.000306	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—pancreatic cancer	9.55e-06	0.000305	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	9.52e-06	0.000304	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—pancreatic cancer	9.37e-06	0.000299	CcSEcCtD
Vandetanib—Diarrhoea—Docetaxel—pancreatic cancer	9.32e-06	0.000298	CcSEcCtD
Vandetanib—Oedema—Epirubicin—pancreatic cancer	9.19e-06	0.000293	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—pancreatic cancer	9.15e-06	0.000292	CcSEcCtD
Vandetanib—Infection—Epirubicin—pancreatic cancer	9.13e-06	0.000291	CcSEcCtD
Vandetanib—Cough—Doxorubicin—pancreatic cancer	9.09e-06	0.00029	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—pancreatic cancer	9.02e-06	0.000288	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—pancreatic cancer	9.01e-06	0.000288	CcSEcCtD
Vandetanib—Dizziness—Docetaxel—pancreatic cancer	9.01e-06	0.000288	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—pancreatic cancer	8.99e-06	0.000287	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—pancreatic cancer	8.99e-06	0.000287	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—pancreatic cancer	8.92e-06	0.000285	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—pancreatic cancer	8.87e-06	0.000283	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—pancreatic cancer	8.87e-06	0.000283	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—pancreatic cancer	8.84e-06	0.000282	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	8.8e-06	0.000281	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—pancreatic cancer	8.67e-06	0.000277	CcSEcCtD
Vandetanib—Vomiting—Docetaxel—pancreatic cancer	8.66e-06	0.000277	CcSEcCtD
Vandetanib—Rash—Docetaxel—pancreatic cancer	8.59e-06	0.000274	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—pancreatic cancer	8.58e-06	0.000274	CcSEcCtD
Vandetanib—Headache—Docetaxel—pancreatic cancer	8.53e-06	0.000272	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—pancreatic cancer	8.5e-06	0.000271	CcSEcCtD
Vandetanib—Infection—Doxorubicin—pancreatic cancer	8.44e-06	0.00027	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	8.37e-06	0.000267	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—pancreatic cancer	8.33e-06	0.000266	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—pancreatic cancer	8.32e-06	0.000266	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—pancreatic cancer	8.31e-06	0.000265	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—pancreatic cancer	8.26e-06	0.000264	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—pancreatic cancer	8.25e-06	0.000263	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—pancreatic cancer	8.19e-06	0.000262	CcSEcCtD
Vandetanib—Nausea—Docetaxel—pancreatic cancer	8.09e-06	0.000258	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—pancreatic cancer	8.09e-06	0.000258	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—pancreatic cancer	7.98e-06	0.000255	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	7.93e-06	0.000253	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—pancreatic cancer	7.92e-06	0.000253	CcSEcCtD
Vandetanib—Pain—Epirubicin—pancreatic cancer	7.85e-06	0.000251	CcSEcCtD
Vandetanib—Constipation—Epirubicin—pancreatic cancer	7.85e-06	0.000251	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	7.74e-06	0.000247	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—pancreatic cancer	7.69e-06	0.000245	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—pancreatic cancer	7.63e-06	0.000244	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—pancreatic cancer	7.58e-06	0.000242	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—pancreatic cancer	7.51e-06	0.00024	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—pancreatic cancer	7.48e-06	0.000239	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—pancreatic cancer	7.39e-06	0.000236	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	7.34e-06	0.000234	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—pancreatic cancer	7.33e-06	0.000234	CcSEcCtD
Vandetanib—Pain—Doxorubicin—pancreatic cancer	7.27e-06	0.000232	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—pancreatic cancer	7.27e-06	0.000232	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—pancreatic cancer	7.26e-06	0.000232	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—pancreatic cancer	7.26e-06	0.000232	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	6.95e-06	0.000222	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—pancreatic cancer	6.72e-06	0.000215	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—pancreatic cancer	6.72e-06	0.000215	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—pancreatic cancer	6.59e-06	0.00021	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—pancreatic cancer	6.5e-06	0.000208	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—pancreatic cancer	6.28e-06	0.000201	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—pancreatic cancer	6.1e-06	0.000195	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—pancreatic cancer	6.07e-06	0.000194	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—pancreatic cancer	6.01e-06	0.000192	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—pancreatic cancer	5.84e-06	0.000187	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—pancreatic cancer	5.82e-06	0.000186	CcSEcCtD
Vandetanib—Rash—Epirubicin—pancreatic cancer	5.79e-06	0.000185	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—pancreatic cancer	5.79e-06	0.000185	CcSEcCtD
Vandetanib—Headache—Epirubicin—pancreatic cancer	5.75e-06	0.000184	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—pancreatic cancer	5.62e-06	0.000179	CcSEcCtD
Vandetanib—Nausea—Epirubicin—pancreatic cancer	5.46e-06	0.000174	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—pancreatic cancer	5.4e-06	0.000173	CcSEcCtD
Vandetanib—Rash—Doxorubicin—pancreatic cancer	5.36e-06	0.000171	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—pancreatic cancer	5.35e-06	0.000171	CcSEcCtD
Vandetanib—Headache—Doxorubicin—pancreatic cancer	5.32e-06	0.00017	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—pancreatic cancer	5.05e-06	0.000161	CcSEcCtD
Vandetanib—PDGFRB—Immune System—PIK3CA—pancreatic cancer	3.36e-07	9.94e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL8—pancreatic cancer	3.36e-07	9.92e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—pancreatic cancer	3.35e-07	9.92e-06	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—pancreatic cancer	3.35e-07	9.91e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—pancreatic cancer	3.35e-07	9.9e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—pancreatic cancer	3.34e-07	9.86e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	3.32e-07	9.8e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CG—pancreatic cancer	3.31e-07	9.78e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—pancreatic cancer	3.3e-07	9.77e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—pancreatic cancer	3.29e-07	9.73e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—pancreatic cancer	3.29e-07	9.72e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—pancreatic cancer	3.29e-07	9.72e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—pancreatic cancer	3.29e-07	9.71e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CD—pancreatic cancer	3.28e-07	9.71e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CASP3—pancreatic cancer	3.28e-07	9.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—STAT3—pancreatic cancer	3.28e-07	9.69e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—pancreatic cancer	3.28e-07	9.69e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—SRC—pancreatic cancer	3.28e-07	9.68e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	3.27e-07	9.67e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—NRAS—pancreatic cancer	3.27e-07	9.67e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGF—pancreatic cancer	3.27e-07	9.66e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—pancreatic cancer	3.26e-07	9.65e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—pancreatic cancer	3.26e-07	9.63e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTEN—pancreatic cancer	3.26e-07	9.63e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—pancreatic cancer	3.25e-07	9.61e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—pancreatic cancer	3.24e-07	9.58e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—pancreatic cancer	3.23e-07	9.55e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—pancreatic cancer	3.22e-07	9.53e-06	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—pancreatic cancer	3.22e-07	9.51e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—pancreatic cancer	3.22e-07	9.51e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CASP3—pancreatic cancer	3.21e-07	9.49e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—CTNNB1—pancreatic cancer	3.21e-07	9.48e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—pancreatic cancer	3.19e-07	9.44e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—pancreatic cancer	3.18e-07	9.4e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CTNNB1—pancreatic cancer	3.16e-07	9.35e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—pancreatic cancer	3.16e-07	9.35e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—pancreatic cancer	3.16e-07	9.34e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—pancreatic cancer	3.16e-07	9.34e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—NRAS—pancreatic cancer	3.15e-07	9.31e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—pancreatic cancer	3.15e-07	9.3e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PTEN—pancreatic cancer	3.13e-07	9.24e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—pancreatic cancer	3.13e-07	9.24e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—pancreatic cancer	3.12e-07	9.23e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—pancreatic cancer	3.11e-07	9.2e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—pancreatic cancer	3.11e-07	9.19e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—pancreatic cancer	3.11e-07	9.19e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—pancreatic cancer	3.1e-07	9.18e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—pancreatic cancer	3.1e-07	9.16e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—pancreatic cancer	3.1e-07	9.15e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTEN—pancreatic cancer	3.08e-07	9.11e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—pancreatic cancer	3.08e-07	9.1e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—pancreatic cancer	3.08e-07	9.09e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	3.07e-07	9.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—pancreatic cancer	3.05e-07	9.01e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—pancreatic cancer	3.05e-07	9.01e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—pancreatic cancer	3.05e-07	9e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—pancreatic cancer	3.05e-07	9e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—pancreatic cancer	3.04e-07	8.99e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—pancreatic cancer	3.04e-07	8.98e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—pancreatic cancer	3.04e-07	8.97e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—pancreatic cancer	3.03e-07	8.96e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—pancreatic cancer	3.03e-07	8.95e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—pancreatic cancer	3.02e-07	8.93e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—pancreatic cancer	3.02e-07	8.92e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—pancreatic cancer	3.01e-07	8.91e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—pancreatic cancer	3.01e-07	8.89e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—pancreatic cancer	3e-07	8.87e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—pancreatic cancer	2.99e-07	8.85e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—pancreatic cancer	2.99e-07	8.83e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—pancreatic cancer	2.99e-07	8.83e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—pancreatic cancer	2.98e-07	8.8e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—pancreatic cancer	2.97e-07	8.78e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CB—pancreatic cancer	2.97e-07	8.78e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—pancreatic cancer	2.96e-07	8.75e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—pancreatic cancer	2.96e-07	8.74e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—pancreatic cancer	2.94e-07	8.68e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—pancreatic cancer	2.94e-07	8.68e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—pancreatic cancer	2.93e-07	8.66e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—pancreatic cancer	2.91e-07	8.59e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—pancreatic cancer	2.87e-07	8.49e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—pancreatic cancer	2.87e-07	8.49e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—pancreatic cancer	2.87e-07	8.47e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—pancreatic cancer	2.86e-07	8.46e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—pancreatic cancer	2.86e-07	8.45e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—pancreatic cancer	2.86e-07	8.45e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—pancreatic cancer	2.85e-07	8.44e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—pancreatic cancer	2.85e-07	8.44e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—pancreatic cancer	2.85e-07	8.41e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—pancreatic cancer	2.84e-07	8.38e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—pancreatic cancer	2.81e-07	8.32e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.8e-07	8.28e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—pancreatic cancer	2.8e-07	8.28e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—pancreatic cancer	2.8e-07	8.27e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—pancreatic cancer	2.8e-07	8.27e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—pancreatic cancer	2.79e-07	8.25e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—pancreatic cancer	2.78e-07	8.23e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—pancreatic cancer	2.77e-07	8.19e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—pancreatic cancer	2.76e-07	8.16e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—pancreatic cancer	2.76e-07	8.15e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—pancreatic cancer	2.76e-07	8.15e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—pancreatic cancer	2.76e-07	8.14e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—pancreatic cancer	2.75e-07	8.14e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—pancreatic cancer	2.75e-07	8.13e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—pancreatic cancer	2.75e-07	8.13e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—pancreatic cancer	2.75e-07	8.12e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—pancreatic cancer	2.74e-07	8.11e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—pancreatic cancer	2.73e-07	8.08e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—pancreatic cancer	2.73e-07	8.08e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—pancreatic cancer	2.73e-07	8.06e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—pancreatic cancer	2.71e-07	8.02e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—pancreatic cancer	2.7e-07	7.98e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—pancreatic cancer	2.7e-07	7.98e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—pancreatic cancer	2.69e-07	7.96e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—pancreatic cancer	2.69e-07	7.95e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—pancreatic cancer	2.69e-07	7.94e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—pancreatic cancer	2.68e-07	7.93e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—pancreatic cancer	2.68e-07	7.91e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—pancreatic cancer	2.67e-07	7.89e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—pancreatic cancer	2.66e-07	7.86e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—pancreatic cancer	2.66e-07	7.85e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—pancreatic cancer	2.66e-07	7.85e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—pancreatic cancer	2.65e-07	7.83e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—pancreatic cancer	2.65e-07	7.83e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—pancreatic cancer	2.64e-07	7.81e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—pancreatic cancer	2.63e-07	7.78e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—pancreatic cancer	2.63e-07	7.78e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—pancreatic cancer	2.6e-07	7.69e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—pancreatic cancer	2.6e-07	7.68e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—pancreatic cancer	2.59e-07	7.66e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—pancreatic cancer	2.59e-07	7.66e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—pancreatic cancer	2.59e-07	7.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—pancreatic cancer	2.58e-07	7.63e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—pancreatic cancer	2.58e-07	7.62e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—pancreatic cancer	2.57e-07	7.59e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—pancreatic cancer	2.56e-07	7.57e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—pancreatic cancer	2.56e-07	7.57e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—pancreatic cancer	2.56e-07	7.55e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—pancreatic cancer	2.54e-07	7.51e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—pancreatic cancer	2.54e-07	7.5e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—pancreatic cancer	2.54e-07	7.5e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—pancreatic cancer	2.54e-07	7.5e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—pancreatic cancer	2.53e-07	7.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD44—pancreatic cancer	2.53e-07	7.49e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—pancreatic cancer	2.51e-07	7.43e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—pancreatic cancer	2.51e-07	7.41e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—pancreatic cancer	2.51e-07	7.41e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—pancreatic cancer	2.5e-07	7.4e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—pancreatic cancer	2.5e-07	7.39e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—pancreatic cancer	2.5e-07	7.38e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—pancreatic cancer	2.49e-07	7.37e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—pancreatic cancer	2.49e-07	7.35e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—pancreatic cancer	2.47e-07	7.31e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—pancreatic cancer	2.47e-07	7.3e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—pancreatic cancer	2.46e-07	7.28e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—pancreatic cancer	2.45e-07	7.25e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—pancreatic cancer	2.44e-07	7.23e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—pancreatic cancer	2.44e-07	7.2e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCG—pancreatic cancer	2.43e-07	7.18e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—pancreatic cancer	2.41e-07	7.14e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—pancreatic cancer	2.41e-07	7.14e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—pancreatic cancer	2.4e-07	7.1e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—pancreatic cancer	2.39e-07	7.07e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—pancreatic cancer	2.39e-07	7.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—pancreatic cancer	2.38e-07	7.04e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—pancreatic cancer	2.37e-07	7e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—pancreatic cancer	2.35e-07	6.94e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—pancreatic cancer	2.33e-07	6.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—pancreatic cancer	2.33e-07	6.89e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—pancreatic cancer	2.32e-07	6.85e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—pancreatic cancer	2.32e-07	6.85e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—pancreatic cancer	2.31e-07	6.81e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—pancreatic cancer	2.3e-07	6.79e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—pancreatic cancer	2.3e-07	6.79e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—pancreatic cancer	2.29e-07	6.78e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—pancreatic cancer	2.29e-07	6.77e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—pancreatic cancer	2.29e-07	6.76e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—STK11—pancreatic cancer	2.28e-07	6.75e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—pancreatic cancer	2.28e-07	6.74e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—pancreatic cancer	2.27e-07	6.71e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—pancreatic cancer	2.25e-07	6.64e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—pancreatic cancer	2.24e-07	6.62e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—pancreatic cancer	2.23e-07	6.6e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—pancreatic cancer	2.21e-07	6.54e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—pancreatic cancer	2.21e-07	6.53e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—pancreatic cancer	2.21e-07	6.52e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—pancreatic cancer	2.21e-07	6.52e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—pancreatic cancer	2.2e-07	6.52e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—pancreatic cancer	2.2e-07	6.51e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—pancreatic cancer	2.19e-07	6.47e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—pancreatic cancer	2.17e-07	6.43e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—pancreatic cancer	2.13e-07	6.3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—pancreatic cancer	2.13e-07	6.29e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—pancreatic cancer	2.13e-07	6.29e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—pancreatic cancer	2.11e-07	6.24e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—pancreatic cancer	2.1e-07	6.22e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—pancreatic cancer	2.1e-07	6.2e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—pancreatic cancer	2.06e-07	6.09e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—pancreatic cancer	2.06e-07	6.08e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—pancreatic cancer	2.05e-07	6.06e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—pancreatic cancer	2.05e-07	6.05e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—pancreatic cancer	2.04e-07	6.03e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—pancreatic cancer	2.04e-07	6.02e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—pancreatic cancer	2.03e-07	5.99e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—pancreatic cancer	2.03e-07	5.99e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	2.02e-07	5.98e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—pancreatic cancer	2.01e-07	5.95e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—pancreatic cancer	2.01e-07	5.94e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—pancreatic cancer	1.98e-07	5.85e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—pancreatic cancer	1.97e-07	5.83e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—pancreatic cancer	1.97e-07	5.82e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.96e-07	5.81e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—pancreatic cancer	1.96e-07	5.79e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—pancreatic cancer	1.95e-07	5.77e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—pancreatic cancer	1.95e-07	5.77e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—pancreatic cancer	1.94e-07	5.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—pancreatic cancer	1.9e-07	5.61e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—pancreatic cancer	1.88e-07	5.55e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—pancreatic cancer	1.82e-07	5.38e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—pancreatic cancer	1.82e-07	5.37e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—pancreatic cancer	1.81e-07	5.35e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—pancreatic cancer	1.8e-07	5.33e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—pancreatic cancer	1.78e-07	5.26e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—pancreatic cancer	1.78e-07	5.25e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—pancreatic cancer	1.77e-07	5.23e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—pancreatic cancer	1.75e-07	5.18e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—pancreatic cancer	1.74e-07	5.16e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—pancreatic cancer	1.74e-07	5.14e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—pancreatic cancer	1.71e-07	5.06e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—pancreatic cancer	1.69e-07	4.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—pancreatic cancer	1.68e-07	4.97e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—pancreatic cancer	1.68e-07	4.95e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—pancreatic cancer	1.65e-07	4.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—pancreatic cancer	1.61e-07	4.77e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—pancreatic cancer	1.6e-07	4.72e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—pancreatic cancer	1.54e-07	4.57e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—pancreatic cancer	1.49e-07	4.42e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—pancreatic cancer	1.48e-07	4.37e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.44e-07	4.26e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—pancreatic cancer	1.43e-07	4.22e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—pancreatic cancer	1.43e-07	4.21e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.39e-07	4.11e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.27e-07	3.75e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—pancreatic cancer	1.26e-07	3.73e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—pancreatic cancer	1.25e-07	3.69e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.1e-07	3.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.09e-07	3.24e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—pancreatic cancer	1.02e-07	3.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—pancreatic cancer	9.55e-08	2.82e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	6.73e-08	1.99e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—pancreatic cancer	5.5e-08	1.63e-06	CbGpPWpGaD
